维普期刊资源整合服务平台（V6.5）

62篇 您的检索式：作者名="Kiladjian"

选中清除导出查看参考文献查看引证文献引用追踪共4页首页上一页第1页下一页末页 /4 跳转

	题名	作者	年代	出处	被引量
1	JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis 显示文摘	HARRISON C KILADJIAN JJ AL-ALI HK	2012	NEnglJMed2012，366，9：	1
2	interferon-alpha therapy in bcr-abl-negative myelopro-liferative neoplasms 显示文摘	Kiladjian JJ Chomienne C Fenaux P	2008	Leukemia2008，22，11：	1
3	Activation of cytotoxic T-ceU receptor γδ T lymphocytes in response to specific stimulation in myelodysplastic syndromes 显示文摘	Jean-Jacques Kiladjian Sylvie Chevret Virginie Eclache et at	2008	Haematologica2008，93，3：	1
4	JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis 显示文摘	Harrison C Kiladjian JJ A1-Ali HK	2012	N Engl J Med2012，366，9：	1
5	Treatment target in polycythemia vera 显示文摘	McMullinMF Harrison CN Kiladjian JJ	2013	N Engl J ned2013，368，16：	1
6	Ruxolitinib versus standard therapy for the treatment of polycythemia vera 显示文摘	Vannucchi AM Kiladjian JJ Griesshammer M	2015	N Eng J Med2015，372，2：	1
7	JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis 显示文摘	Harrison C Kiladjian JJ A1-Ali HK	2012	N Engl J Med2012，366，9：	1
8	Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipebroman in polycythemia vera and essential thrombocythemia显示文摘	Kiladjian JJ Rain JD Bernard JF	2006	Semin Thromb Hemost2006，32，42：	1
9	Interferonalpha therapy in bcr-abl-negative myeloproliferative neoplasms显示文摘	Kiladjian JJ Chomienne C Fenaux P	2008	Leukemia2008，22，11：	1
10	Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980 显示文摘	Kiladjian JJ Chevret S Dosquet C	2011	J Clin Oncol2011，29，29：	1
11	Pure red-cell aplasia and antierythropoietia antibodies in patients treated with recombinant erythropoietin显示文摘	Casadevall N Nataf J Viron B Kolta A Kiladjian JJ Philippe MD	2002	N Engl J Med2002，346，7：	1
12	Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera显示文摘	Kiladjian JJ Cassinat B Chevret S	2008	Blood2008，112，8：	1
13	Cytolytic function and sur-vival of natural killer cells are severely altered in myelodysplastic syn- dromes 显示文摘	Kiladjian JJ Bourgeois E Lobe I	2006	Leukemia2006，20，3：	1
14	Activation of cytotoxic T-cell receptor gammadelta T lymphocytes in response to specific stimulation in myelodysplastic syndromes显示文摘	Kiladjian J J Visentin G Viey E		0，，03：	1
15	Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2Vrl7F clones without affecting TET2 mutant cells 显示文摘	Kiladjian JJ Masse A Cassinat B	2010	Leukemia2010，24，8：	1
16	JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis 显示文摘	Harrison C Kiladjian JJ A1 - Ali HK	2012	New Engl J Med2012，366，：	1
17	Pegylated interferon-alfa- 2a induces complete hematologic and molecular response s with low toxicity in polycythemia vera 显示文摘	Kiladjian JJ Cassinat B Chevret S	2008	Blood2008，112，8：	1
18	JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis 显示文摘	Harrison C Kiladjian JJ A1-Ali HK	2012	N Engl J Med2012，366，9：	1
19	Pegylated interferon- alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera 显示文摘	Kiladjian JJ Cassinat B Chevret S	2008	Blood2008，112，8：	1
20	Ruxolitinib versus standard therapy for the treatment of polycythemia vera 显示文摘	Vannucchi AM Kiladjian JJ Griesshammer M	2015	N Engl J Med2015，372，5：	1

返回顶部每页显示：

共4页首页上一页第1页下一页末页 /4 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示